Reviews
Vol. 5 No. 3 (2026): In memory of Armando D’Angelo
Lupus anticoagulant: a never-ending story. New insights from anti prothrombin antibodies
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 28 August 2026
0
Views
0
Downloads
Authors
Until recently, the lupus anticoagulant (LA) phenomenon was largely attributed to antibodies directed against β2-glycoprotein I (β2GPI). However, this explanation does not account for LA activity in patients with isolated LA, in whom anti-β2GPI antibodies are absent. Increasing evidence indicates that anti-prothrombin (aPT) antibodies play a key role in these cases. aPT antibodies detected with the anti-phosphatidyl-serine/prothrombin (aPS/PT) test appear to explain the coagulation inhibition observed in most patients with isolated LA. They also represent a major determinant of LA activity in triple-positive patients (LA, aCL, and aβ2GPI). Because false-positive LA results frequently occur in patients receiving oral anticoagulants, detection of aPT antibodies may represent a useful surrogate marker of LA. In vitro, some aPT antibodies can induce activated protein C resistance, contributing to the hypercoagulable state promoted by aβ2GPI antibodies. However, aPT antibodies are also involved in LA/hypoprothrombinemia syndrome, which is a bleeding disorder. In this case, aPT antibodies contribute to causing severe hypoprothrombinemia by promoting rapid prothrombin clearance. These observations suggest three biological patterns of LA: i) procoagulant LA in triple-positive patients at high thrombotic risk, typically associated with high-titer IgG aPT antibodies detected by aPS/PT test. ii) Mildly procoagulant LA in patients with isolated LA, generally associated with moderate-to-high-titer IgM aPT antibodies detected by aPS/PT test. iii) Anticoagulant LA, characterized by very high titers of aPT antibodies detected by aPS/PT test associated with hypoprothrombinemia and bleeding. Recognition of these mechanisms is refining the interpretation of LA and providing new insights into the pathophysiology of antiphospholipid syndrome.
Downloads
Download data is not yet available.
Citations
1. Pengo V, Bison E, Denas G, et al. The paradox of the lupus anticoagulant: history and perspectives. Semin Thromb Hemost 2014;40:860-5.
2. Pengo V, Thiagarajan P, Shapiro SS, Heine MJ. Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 1987;70:69-76.
3. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
4. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120-4.
5. Matsuura E, Igarashi Y, Fujimoto M, et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336:177-8.
6. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005;105:1540-5.
7. Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005;93:1147-52.
8. Bevers EM, Galli M, Barbui T, et al. Lupus anticoagulant IgG's are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66:629-32.
9. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982-93.
10. Simmelink MJ, Derksen RH, Arnout J, de Groot PG. A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003;1:740-7.
11. Pengo V, Biasiolo A, Pegoraro C, Iliceto S. A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004;2:702-7.
12. Pengo V, Del Ross T, Ruffatti A, et al. Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns. Thromb Res 2018;172:172-8.
13. Bontadi A, Ruffatti A, Falcinelli E, et al. Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. Thromb Haemost 2013;109:901-8.
14. Pontara E, Cheng C, Cattini MG, et al. An in vitro model to mimic the thrombotic occlusion of small vessels in catastrophic antiphospholipid syndrome (CAPS). Lupus 2019;28:1663-8.
15. Proulle V, Furie RA, Merrill-Skoloff G, et al. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood 2014;124:611-22.
16. Pontara E, Cattini MG, Cheng C, et al. Insight into the hypercoagulable state of high-risk thrombotic APS patients: contribution of abeta2GPI and aPS/PT antibodies. J Thromb Haemost 2021;19:805-13.
17. Pengo V, Testa S, Martinelli I, et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb Res 2015;135:46-9.
18. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011;118:4714-8.
19. Cattini MG, Bison E, Pontara E, et al. Tetra positive thrombotic antiphospholipid syndrome: major contribution of anti-phosphatidyl-serine/prothrombin antibodies to lupus anticoagulant activity. J Thromb Haemost 2020;18:1124-32.
20. Pontara E, Bison E, Cattini MG, et al. Close link between antiphosphatidylserine/prothrombin antibodies, lupus anticoagulant, and activated protein C resistance in tetra antiphospholipid antibody-positive subjects. J Thromb Haemost 2023;21:3138-44.
21. Pengo V, Biasiolo A, Gresele P, et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 2007;5:925-30.
22. Favaloro EJ, Pasalic L. Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants. Res Pract Thromb Haemost 2022;6:e12676.
23. Tripodi A. Diagnostic challenges on the laboratory detection of lupus anticoagulant. Biomedicines 2021;9:995.
24. Tripodi A, Mancuso ME, Chantarangkul V, et al. Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. Clin Chem 2005;51:1883-5.
25. van Rossum AP, Vlasveld LT, van den Hoven LJ, et al. False prolongation of the activated partial thromboplastin time in inflammatory patients: interference of C-reactive protein. Br J Haematol 2012;157:394-5.
26. Nelson Strande BJ, Sridharan M, Leger RR, et al. Effect of residual platelets in frozen-thawed plasma on results of dilute Russell's viper venom time assay for lupus anticoagulant testing. Am J Clin Pathol 2024;161:212-5.
27. Ten Boekel E, Bartels P. Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1+2, D-dimer and FVIII:C. Pathophysiol Haemost Thromb 2002;32:137-42.
28. Pengo V, Zardo L, Cattini MG, et al. Prothrombin is responsible for the lupus cofactor phenomenon in a patient with lupus anticoagulant/hypoprothrombinemia syndrome. TH Open 2020;4:e40-4.
29. Tonello M, Bison E, Cattini MG, et al. Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant: is their presence linked to dual test positivity? Clin Chem Lab Med 2021;59:1950-3.
30. Moore GW, Foxton E, Platton S, et al. Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay. J Thromb Haemost 2023;21:3539-46.
31. Moore GW. Lupus anticoagulant testing: dilute prothrombin time (dPT). Methods Mol Biol 2023;2663:275-88.
32. Moore GW, Jones PO, Platton S, et al. International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. J Thromb Haemost 2021;19:3177-92.
33. Tripodi A, Scalambrino E, Chantarangkul V, et al. Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection. Thromb Res 2021;204:32-9.
34. Zhu R, Cheng CY, Yang Y, et al. Prevalence of aPhosphatidylserine/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: a systematic review and meta-analysis. Thromb Res 2022;214:106-14.
35. Pengo V, Banzato A, Bison E, et al. Laboratory testing for antiphospholipid syndrome. Int J Lab Hematol 2016;38:27-31.
36. Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syndrome: antibodies to domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015;13:782-7.
37. Pengo V. Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome: response from Pengo. J Thromb Haemost 2020;18:3118-9.
38. Monti M, Martini T, Pengo V, et al. Association between severe acute respiratory syndrome coronavirus 2 infection (coronavirus disease 2019) and lupus anticoagulant-hypoprothrombinemia syndrome: a case report and literature assessment. Semin Thromb Hemost 2023;49:558-60.
39. Pengo V, Zardo L, Cattini MG, et al. Prothrombin is responsible for the lupus cofactor phenomenon in a patient with lupus anticoagulant/hypoprothrombinemia syndrome. TH Open 2020;4:e40-4.
40. Chinnaraj M, Planer W, Pengo V, Pozzi N. Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis. Blood Adv 2019;3:1738-49.
41. Kumar S, Summers B, Basore K, et al. Cryo-EM structure and functional basis of prothrombin recognition by a type I antiprothrombin antiphospholipid antibody. Blood 2024;143:2005-11.
42. Pozzi N, Pontara E, Kumar S, Pengo V. Understanding the difference between type I and type II antiprothrombin antibodies and their effect on activated protein C resistance. J Thromb Haemost 2024;22:2935-8.
How to Cite
1.
Pengo V. Lupus anticoagulant: a never-ending story. New insights from anti prothrombin antibodies. Bleeding Thromb Vasc Biol [Internet]. 2026 Aug. 28 [cited 2026 Aug. 28];5(3). Available from: https://www.btvb.org/btvb/article/view/469
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Paolo Simioni, Vittorio Pengo, Paolo Prandoni, Thrombosis and hemostasis at the University of Padua: a reappraisal on the occasion of its 800th year of history , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Daniela Poli, Walter Ageno, Emilia Antonucci, Salvatore Bradamante, Eugenio Bucherini, Paolo Chiarugi, Antonio Chistolini, Benilde Cosmi, Anna Falanga, Antonio Insana, Domenico Lione, Rosa Maria Lombardi, Giuseppe Malcangi, Rossella Marcucci, Giuliana Martini, Lucilla Masciocco, Carmelo Paparo, Daniele Pastori, Simona Pedrini, Vittorio Pengo, Pasquale Pignatelli, Andrea Toma, Sophie Testa, Gualtiero Palareti, Management of anticoagulation in atrial fibrillation patients in Italy: insight from the Atrial Fibrillation-Survey on Anticoagulated Patients Register (AF-START) , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Gualtiero Palareti, Paolo Prandoni, Cristina Legnani, Emilia Antonucci, Serena Zorzi, Alberto Tosetto, Lorenza Bertù, Sophie Testa, Vittorio Pengo, Walter Ageno, Ida Martinelli, Benilde Cosmi, Eugenio Bucherini, Daniela Poli, Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Vittorio Pengo, Luca Sarti, Emilia Antonucci, Stefania Di Agostino, Elisa Bison, Gentian Denas, Daniela Poli, Pier Luigi Meroni, Roberto Gerli, Antonella Radice, Gualtiero Palareti, on behalf of FIRMA group and START collaborators, Descriptive analysis of patients positive for anti-phospholipid antibodies included in two Italian registries , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Vittorio Pengo, Comment on "Apixaban vs. aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischemic attack: subgroup analysis of the ARTESiA randomized controlled trial" , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 2 (2025)
